Abstract
Due to the rapid approval of some of the newer therapies for COVID-19 infection, there are several pharmacologic aspects of these therapies that are not fully known, including drug-drug interactions. Transplant recipients face notable risks in relation to these interactions. This article outlines complications arising from the concurrent administration of nirmatrelvir/ritonavir and tacrolimus in a patient with history of combined kidney and liver transplantation. Additionally, it highlights the effective utilization of phenytoin as an inducer to correct the supratherapeutic levels of tacrolimus.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
